Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin in Relapsed or Refractory DLBCL
NCT00042666Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2002
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in diffuse large B-cell lymphoma (DLBCL), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles up to 34.3 months. Started Jun 2002; status: completed.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00042666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042666.